Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

Hepatology

Volumn 35, Issue 5, 2002, Pages 1002-1009

  Lau, Johnson Y N ^a   Tam, Robert C ^a   Liang, T Jake ^b   Hong, Zhi ^a  

^a Valeant Pharmaceuticals International   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; DNA REPLICATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS HEPATITIS; VIRUS REPLICATION;

EID: 0036240477     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.32672     Document Type: Article

References (50)

1. Design, synthesis, and broad spectrum antiviral activity of 1-β-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide and related nucleosides
2. Broad-spectrum antiviral activity of virazole: 1-Beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide
3. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
4. Interferons in host defense
5. Mechanisms of hepatic toxicity. IV. Pathogenetic mechanisms involved in hepatitis C virus-induced liver diseases
6. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
7. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
8. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication
9. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo
10. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase
11. A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase
12. HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma
13. The expanding universe of T cell subsets: Th1, Th2 and more
14. Detection of type 2-like T helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity
15. Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C
16. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection
17. Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and post-treatment with interferon alfa
18. In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: Failure in IL-2 production despite proliferation
19. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia
20. Inhibition of plaque-forming cell responses in vivo by ribavirin
21. Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: A preliminary report
22. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile
23. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology
24. The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels
25. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level
26. The antiviral compound ribavirin modulates the T helper Th1/Th2 subset balance in hepatitis B and C virus-specific immune responses
27. Ribavirin inhibits viral-induced macrophage production of tumor necrosis factor, interleukin-1, procoagulant activity fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response
28. Enhancement of hepatitis C virus-specific type 1 cytokine and T cell proliferative responses by ribavirin and levovirin (ICN17261) in vitro
29. Direct evidence for the immunomodulatory action of ribavirin on T-cell reactivity to hepatitis C virus (HCV)
30. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients
31. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha
32. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C
33. Improved cell-mediated immune responses to HCV antigens after combination therapy
34. Peripheral cellular immune responses during Rebetron therapy for chronic HCV infection
35. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C
36. Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy
37. Phase I clinical studies of levovirin - A second generation ribavirin candidate
38. Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line
39. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors
40. Novel mycophenolic adenine bis(phosphonate)s as potential imm0unosuppressants
41. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon
42. Characterization of interferon-alfa-2a and pegylated interferon-alfa-2a in combination with ribavirin, mycophenolic acid or VX-497 as inhibitors of HCV replicon replication
43. Background and mechanisms of action of ribavirin
44. Inhibition of lymphocyte proliferative responses by ribavirin
45. Dose range-finding study of VX-497, a novel, oral IMPDH inhibitor, in patients with hepatitis C
46. Genetic heterogeneity of hepatitis C virus and its clinical implications
47. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
48. RNA virus error catastrophe: Direct molecular test by using ribavirin
49. Ribavirin induces error prone replication of GBV-B in primary tamarin hepatocytes
50. 14C-ribavirin distribution and pharmacokinetic studies in rat, baboons, and man